CN1192799C - 佐剂组合制剂 - Google Patents

佐剂组合制剂 Download PDF

Info

Publication number
CN1192799C
CN1192799C CNB008074895A CN00807489A CN1192799C CN 1192799 C CN1192799 C CN 1192799C CN B008074895 A CNB008074895 A CN B008074895A CN 00807489 A CN00807489 A CN 00807489A CN 1192799 C CN1192799 C CN 1192799C
Authority
CN
China
Prior art keywords
mpl
adjuvant
csf
peptide
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008074895A
Other languages
English (en)
Chinese (zh)
Other versions
CN1354675A (zh
Inventor
M·哈根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Wyeth Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings LLC filed Critical Wyeth Holdings LLC
Publication of CN1354675A publication Critical patent/CN1354675A/zh
Application granted granted Critical
Publication of CN1192799C publication Critical patent/CN1192799C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Beans For Foods Or Fodder (AREA)
CNB008074895A 1999-05-13 2000-05-12 佐剂组合制剂 Expired - Fee Related CN1192799C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13396399P 1999-05-13 1999-05-13
US60/133,963 1999-05-13

Publications (2)

Publication Number Publication Date
CN1354675A CN1354675A (zh) 2002-06-19
CN1192799C true CN1192799C (zh) 2005-03-16

Family

ID=22461127

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008074895A Expired - Fee Related CN1192799C (zh) 1999-05-13 2000-05-12 佐剂组合制剂

Country Status (28)

Country Link
US (2) US7611721B1 (https=)
EP (1) EP1178825B1 (https=)
JP (2) JP4974414B2 (https=)
KR (1) KR100863367B1 (https=)
CN (1) CN1192799C (https=)
AT (1) ATE516046T1 (https=)
AU (1) AU781469B2 (https=)
BG (1) BG106094A (https=)
BR (1) BR0010539A (https=)
CA (2) CA2372181C (https=)
CZ (1) CZ20013916A3 (https=)
EA (1) EA006233B1 (https=)
EE (1) EE200100597A (https=)
ES (1) ES2367625T3 (https=)
GE (1) GEP20053446B (https=)
HR (1) HRP20010839A2 (https=)
HU (1) HUP0201220A3 (https=)
ID (1) ID30407A (https=)
IL (2) IL146382A0 (https=)
IS (1) IS6156A (https=)
MX (1) MXPA01011499A (https=)
NO (1) NO20015523L (https=)
NZ (1) NZ515322A (https=)
PL (1) PL352312A1 (https=)
SK (1) SK16022001A3 (https=)
TR (1) TR200103266T2 (https=)
UA (1) UA76406C2 (https=)
WO (1) WO2000069456A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
NZ515322A (en) 1999-05-13 2004-03-26 Wyeth Corp Adjuvant combination formulations
DE60117164T2 (de) * 2000-11-07 2006-08-03 Immuno Vaccine Technologies Inc., Halifax Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
IL155690A0 (en) 2000-11-10 2003-11-23 Wyeth Corp Adjuvant combination formulations
CN106310293A (zh) 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
BRPI0818287A2 (pt) * 2007-10-08 2015-11-03 Intrexon Corp células dendríticas manipuladas e usos para o tratamento do câncer.
WO2009146523A1 (en) 2008-06-05 2009-12-10 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
GB201113570D0 (en) * 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
RU2496149C1 (ru) * 2012-06-19 2013-10-20 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") Способ оценки противооспенной активности лечебно-профилактических препаратов
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
EP4049665B1 (en) 2016-03-15 2025-03-12 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US6294322B1 (en) 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US5939074A (en) 1986-12-30 1999-08-17 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptide antigens
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5993819A (en) * 1987-09-08 1999-11-30 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection
US5019387A (en) 1987-09-08 1991-05-28 Duke University Production of antibodies to HIV
US5013548A (en) 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5223254A (en) 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
CA1340506C (en) 1987-11-24 1999-04-20 Nicholas H. Carbonetti Production of gonorrheal pi proteins and vaccines
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE140483T1 (de) 1988-11-10 1996-08-15 Genetics Inst Natürlicher killerzellen-stimulationsfaktor
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
DE3934366A1 (de) 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
DE69126304T2 (de) 1990-04-27 1997-09-04 Mcmichael, John, Delanson, N.Y. Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
CA2124691A1 (en) 1991-12-02 1993-06-10 Jagannadha K. Sastry Compositions for eliciting cytotoxic t-lymphocyte responses against viruses
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
AU4662393A (en) 1992-07-08 1994-01-31 Schering Corporation Use of gm-csf as a vaccine adjuvant
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
DE69426077T3 (de) 1993-05-25 2004-09-02 Wyeth Holdings Corp. Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
ATE221786T1 (de) * 1994-04-29 2002-08-15 Univ Duke Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus
AUPM543894A0 (en) 1994-05-04 1994-05-26 Commonwealth Scientific And Industrial Research Organisation An adjuvant
WO1996010423A1 (en) 1994-09-30 1996-04-11 Ludwig Institute For Cancer Research COMPOSITIONS CONTAINING A p53 DERIVED PROTEIN OR PEPTIDE, AN ADJUVANT, AND INTERLEUKIN-12 AND USES THEREOF
DK0784486T3 (da) 1994-10-05 2006-08-14 Univ Vanderbilt Interleukin-12 som en adjuvans til Paramyxoviridae-vacciner
JP3958360B2 (ja) * 1995-02-24 2007-08-15 キャンタブ ファーマシューティカルズ リサーチ リミティド 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
US6613337B1 (en) 1997-02-12 2003-09-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
PL328096A1 (en) 1996-02-01 1999-01-04 North American Vaccine Expression of external membrane (mb3) protein of neisseria meningitidis of b group in yeasts and vaccines
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5762943A (en) 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
AU724743B2 (en) 1996-05-31 2000-09-28 Genetics Institute, Llc IL-12 as an adjuvant for Bordetella Pertussis vaccines
US6024965A (en) 1996-10-18 2000-02-15 Erasums University Rotterdam Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
AU729579B2 (en) * 1996-10-23 2001-02-01 Trustees Of The University Of Pennsylvania, The Immunotherapy and improved vaccines
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US6350456B1 (en) * 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
WO1998056415A1 (en) * 1997-06-11 1998-12-17 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
JP2002509545A (ja) 1997-07-08 2002-03-26 カイロン コーポレイション Ｄｎａワクチンを伴うサブミクロン水中油型エマルジョンの使用
IS4518A (is) 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
EP1053016A2 (en) 1998-02-12 2000-11-22 American Cyanamid Company Vaccines comprising interleukin-12 and respiratory syncytial viral antigens
JP2002502884A (ja) 1998-02-12 2002-01-29 アメリカン・サイアナミド・カンパニー インターロイキン−１２および単純ヘルペスウイルス抗原を含んでなるワクチン
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
GB9907860D0 (en) 1999-04-07 1999-06-02 Smithkline Beecham Biolog Novel compounds
NZ515322A (en) 1999-05-13 2004-03-26 Wyeth Corp Adjuvant combination formulations

Also Published As

Publication number Publication date
ID30407A (id) 2001-11-29
WO2000069456A2 (en) 2000-11-23
JP2012006949A (ja) 2012-01-12
JP2004504260A (ja) 2004-02-12
KR20020001873A (ko) 2002-01-09
GEP20053446B (en) 2005-02-25
AU4847300A (en) 2000-12-05
US20100233117A1 (en) 2010-09-16
US7611721B1 (en) 2009-11-03
EP1178825A2 (en) 2002-02-13
EA200101198A1 (ru) 2002-04-25
BR0010539A (pt) 2002-02-19
MXPA01011499A (es) 2002-06-04
IL146382A0 (en) 2002-07-25
NZ515322A (en) 2004-03-26
CA2767116A1 (en) 2000-11-23
EP1178825B1 (en) 2011-07-13
JP5230780B2 (ja) 2013-07-10
ATE516046T1 (de) 2011-07-15
UA76406C2 (en) 2006-08-15
ES2367625T3 (es) 2011-11-07
CA2372181A1 (en) 2000-11-23
CZ20013916A3 (cs) 2002-06-12
CA2372181C (en) 2012-04-17
HUP0201220A3 (en) 2004-07-28
KR100863367B1 (ko) 2008-10-13
EA006233B1 (ru) 2005-10-27
JP4974414B2 (ja) 2012-07-11
HRP20010839A2 (en) 2003-02-28
IS6156A (is) 2001-11-12
IL146382A (en) 2007-07-04
TR200103266T2 (tr) 2002-01-21
BG106094A (en) 2002-05-31
NO20015523D0 (no) 2001-11-12
HUP0201220A2 (en) 2002-08-28
AU781469B2 (en) 2005-05-26
SK16022001A3 (sk) 2002-09-10
CN1354675A (zh) 2002-06-19
EE200100597A (et) 2003-02-17
PL352312A1 (en) 2003-08-11
WO2000069456A3 (en) 2001-02-08
NO20015523L (no) 2002-01-02

Similar Documents

Publication Publication Date Title
CN1192799C (zh) 佐剂组合制剂
CN1282656C (zh) 来自gagp17和p24保守区域的HIV肽以及它们在例如疫苗中的应用
CN1229501C (zh) Hiv多包膜蛋白疫苗的重组痘苗载体混合物
CN1197618C (zh) 突变霍乱全毒素佐剂
CN1188519C (zh) 包含HIV－1Tat和/或Nef蛋白的融合蛋白
CN1297316C (zh) 作为佐剂的霍乱全毒素的突变体形式
CN1541111A (zh) 作为佐剂的霍乱全毒素的突变形式
CN1701788A (zh) 禽多核苷酸疫苗制剂
CN1468089A (zh) 用于传送异源核酸的微粒体
CN1561389A (zh) 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
CN1346367A (zh) Hiv肽,抗原,疫苗组合物,检测hiv所诱导的抗体的免疫测定试剂盒及方法
CN1606624A (zh) 疫苗
CN1846786A (zh) 与佐剂一起注射的重组活疫苗
CN1868545A (zh) 改良疫苗
CN1764474A (zh) 免疫原性组合物及方法
CN1259422C (zh) 呼吸合胞病毒的吸附(g)蛋白衍生的肽
CN101035558A (zh) 对抗布拉迪斯拉发钩端螺旋体和其他病原体的多价犬疫苗
CN1281748C (zh) 为改善IL－12活性而突变的IL－12p40亚基基因及其作为DNA疫苗佐剂的用途
CN1889963A (zh) 方法
CN1812810A (zh) 针对fiv感染的免疫接种材料和方法
CN1458936A (zh) 来自Tat、Rev和Nef保守区的HIV肽以及它们作为例如疫苗组分的应用
CN1124013A (zh) 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物
CN1639569A (zh) 诱导免疫应答的方法和组合物
CN101048178A (zh) 作为疫苗的重组分枝杆菌和生物活性剂的组合
CN1768079A (zh) 多肽

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050316

Termination date: 20100512